New stock news | Deisai Bio successfully passed the hearing of the Hong Kong Stock Exchange, sprinting to become the "first stock of medical imaging big models".

On March 15, the Hong Kong Stock Exchange disclosed that Hangzhou Desheng Biological Technology Co., Ltd. successfully passed the listing hearing on the main board of the Hong Kong Stock Exchange, aiming to become the "first stock of medical imaging big models". As the creator of the world's only and largest-scale medical imaging base model, its listing process has made key progress again. Established in 2016, Desheng Biological, as a national specialized and innovative "small giant" enterprise, focuses on the research, development, production, and commercialization of intelligent medical imaging products and services. It has built a comprehensive solution system consisting of "medical imaging software and medical equipment - reagents and consumables - technology license", covering high-potential clinical fields such as reproductive health and hematological malignancies. It was selected as the number one in the country in the field of AI medical devices and genetics by the Ministry of Industry and Information Technology, and is renowned as a benchmark in domestic medical AI. The core pain point in the current medical industry is evident: the long period to cultivate good doctors, the extreme scarcity of top diagnostic doctors, uneven distribution of high-quality medical resources, difficulty in seeking medical treatment, and difficulty in diagnosis have long been obstacles on the path to national health. If an AI diagnostic system that rivals top doctors could be created, it could not only solve the resource dilemma but also benefit all humanity. This is the core logic behind global capital and national policies rushing to deploy medical AIDesheng Biological is focusing on this pain point and will launch the iMedImage medical image universal big model by 2025. It aims to create the world's first multimodal medical image base model with parameters reaching the billion level, supporting 19 image modalities such as CT, MRI, ultrasound, pathology, chromosomes, etc., covering over 90% of clinical medical imaging scenarios. It becomes the only "AI medical imaging whole process" solution provider in China, offering "base model - intelligent medical equipment - reagents and consumables - big model services" end-to-end AI medical imaging solution portfolio to meet the full-cycle needs from the laboratory to the clinic. Worth mentioning is that iMedImage has an astonishing accuracy rate of 99.86% in "one-click chromosomal analysis" in the field of medical imaging AI, enabling it to stand out and take the lead. It has broken the long-term industry monopoly of international giants such as Carl Zeiss and Leica. In the field of chromosomal karyotype analysis in China, its market share reaches as high as 30.6%, ranking first. According to the authoritative forecast by Frost & Sullivan, by 2035, the scale of the medical AI industry in China will soar from the current 5 billion to the billion level, with a growth space exceeding 20 times, and the industry bonus period will be fully opened. As a leader in the AI medical race, Desheng Biological will enjoy the core bonus of the industry outbreak. In terms of revenue, total revenue increased from RMB 52.844 million in 2023 to RMB 70.352 million in 2024, a year-on-year increase of 33.1%; revenue in the first nine months of 2025 further soared to RMB 112 million, a 469.8% increase from the same period of the previous year. In the first three quarters of 2025, the proportion of technology licensing revenue reached 51.4%, becoming the largest source of revenue. Revenue from medical imaging software and medical equipment grew by 281.2% year-on-year, and sales of AutoVision and MetaSight increased by 40.9% and 160.0% respectively, driving up the average selling price. In terms of profitability, the company's gross profit margin remains at a relatively high level: 71.0% in 2023, 65.5% in 2024, and 75.9% in the first nine months of 2025, with a high gross profit margin of 96.5% in the technology licensing business, showcasing the high value-added nature of its core technology. By passing the hearing of the Hong Kong Stock Exchange, Desheng Biological will leverage the power of the capital market to promote the development of AI medical imaging towards more precise, efficient, and inclusive directions, becoming a key force leading the new era of global precision diagnosis.